Deal Announcements

Actinobac Biomed Receives Venture Capital Commitment

Tuesday, March 24, 2009 5:58:00 AM PDT | VentureDeal Staff

New Brunswick, New Jersey  --  Biotechnology company Actinobac Biomed has received a $500,000 commitment, according to a company announcement.

Actinobac is developing a therapeutic agent "targeting white leukemic blood cells for the treatment of hematological malignancies, including leukemia, myeloma and lymphoma."

The Foundation Venture Capital Group made the capital commitment. The company did not disclose how it would use the funding proceeds.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1